References
- Visani G, Finelli C, Castelli U, Petti M C, Ricci P, Vianelli N, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4–9
- Dupriez B, Morel P, Demory J L, Lai J L, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018
- Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, et al. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640
- Njoku O S, Lewis S M, Catovsky D, Gordon-Smith E C. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 1983; 54: 79–89
- Tefferi A, Mesa R A, Schroeder G, Hanson C A, Li C Y, Dewald G W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763–771
- Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990; 34: 291–300
- Kvasnicka H M, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997; 80: 708–719
- Kreft A, Weiss M, Wiese B, Choritz H, Buhr T, Busche G, et al. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method. Ann Hematol 2003; 82: 605–611
- Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni M F, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994; 68: 205–212
- Barosi G, Berzuini C, Liberato L N, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70: 397–401
- Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983; 62: 353–371
- Rusten L S, Jacobsen S E. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995; 85: 989–996
- Selleri C, Sato T, Anderson S, Young N S, Maciejewski J P. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538–546
- Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954–2970
- Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4146
- Bench A J, Cross N C, Huntly B J, Nacheva E P, Green A R. Myeloproliferative disorders. Best Pract Res Clin Haematol 2001; 14: 531–551
- Hennessy B T, Thomas D A, Giles F J, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer 2005; 103: 32–43